Trials / Not Yet Recruiting
Not Yet RecruitingNCT07019337
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, multi-cohort, phase II study to evaluate the efficacy and safety of Oral metronomic capecitabine combined with pyrotinib in patients with HER2-positive advanced breast cancer who had received prior anti-HER2 ADC drugs (including T-DXd, SHR-A1811, T-DM1, etc.) before treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyrotinib | 400mg or 320mg qd |
| DRUG | Capecitabine | 500mg tid |
Timeline
- Start date
- 2025-06-30
- Primary completion
- 2028-07-31
- Completion
- 2030-12-31
- First posted
- 2025-06-13
- Last updated
- 2025-06-13
Source: ClinicalTrials.gov record NCT07019337. Inclusion in this directory is not an endorsement.